Next Article in Journal
Identification of Two Novel Linear Neutralizing Epitopes within the Hexon Protein of Canine Adenovirus Using Monoclonal Antibodies
Next Article in Special Issue
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
Previous Article in Journal
Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients
Previous Article in Special Issue
Advancements in mRNA Encoded Antibodies for Passive Immunotherapy
Review

HIV mRNA Vaccines—Progress and Future Paths

1
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
2
Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Ralph A. Tripp
Vaccines 2021, 9(2), 134; https://doi.org/10.3390/vaccines9020134
Received: 13 January 2021 / Revised: 27 January 2021 / Accepted: 2 February 2021 / Published: 7 February 2021
(This article belongs to the Special Issue The Past, Present, and Future of mRNA Vaccines)
The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly, an mRNA-based vaccine relies on the host’s cells to manufacture protein immunogens which, in turn, are targets for antibody and cytotoxic T cell responses. mRNA-based vaccines have been the subject of research for over three decades as a platform to protect against or treat a variety of cancers, amyloidosis and infectious diseases. In this review, we discuss mRNA-based approaches for the generation of prophylactic and therapeutic vaccines to HIV. We examine the special immunological hurdles for a vaccine to elicit broadly neutralizing antibodies and effective T cell responses to HIV. Lastly, we outline an mRNA-based HIV vaccination strategy based on the immunobiology of broadly neutralizing antibody development. View Full-Text
Keywords: HIV; vaccine; messenger RNA HIV; vaccine; messenger RNA
Show Figures

Figure 1

MDPI and ACS Style

Mu, Z.; Haynes, B.F.; Cain, D.W. HIV mRNA Vaccines—Progress and Future Paths. Vaccines 2021, 9, 134. https://doi.org/10.3390/vaccines9020134

AMA Style

Mu Z, Haynes BF, Cain DW. HIV mRNA Vaccines—Progress and Future Paths. Vaccines. 2021; 9(2):134. https://doi.org/10.3390/vaccines9020134

Chicago/Turabian Style

Mu, Zekun, Barton F. Haynes, and Derek W. Cain. 2021. "HIV mRNA Vaccines—Progress and Future Paths" Vaccines 9, no. 2: 134. https://doi.org/10.3390/vaccines9020134

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop